CD274 and non-small cell lung carcinoma: As a consequence of the results from the PEARLS/KEYNOTE-091 trial, pembrolizumab has been recently approved for use in the United States and the European Union as an adjuvant treatment option for patients with resected stage IB-IIIA NSCLC, with or without previous chemotherapy and with any PDL-1 expression.